Capricor Therapeutics (CAPR) Other Operating Expenses (2019 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Other Operating Expenses of -$81143.0 for Q1 2026, up 46.15% year-over-year from -$55521.8 in Q1 2025, and down 1085.26% quarter-over-quarter from -$6846.0 in Q3 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Other Operating Expenses (2019 - 2026) Analysis & Trends
Capricor Therapeutics' Other Operating Expenses history runs 8 years deep, the most recent figure standing at -$81143.0 for Q1 2026.
- In Q1 2026, Other Operating Expenses rose 46.15% year-over-year to -$81143.0; the TTM figure through Mar 2026 stood at -$87989.0 (up 93.26% YoY), while the FY2025 annual figure was -$157519.0, down 39.64% from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$81143.0, down from -$6846.0 in the prior quarter.
- The five-year high for Other Operating Expenses was $17389.0 in Q2 2023, with the low at -$1.1 million in Q3 2024.
- The 5-year median for Other Operating Expenses is -$13649.0 (2024), against an average of -$113244.7.
- The sharpest annual moves came in 2023 and 2024: Other Operating Expenses surged 149.81% in 2023, then tumbled 21063.16% in 2024.
- Capricor Therapeutics' Other Operating Expenses stood at -$34266.0 in 2022, then jumped by 98.09% to -$653.0 in 2023, then sank by 1990.2% to -$13649.0 in 2024, then soared by 49.84% to -$6846.0 in 2025, then tumbled by 1085.26% to -$81143.0 in 2026.
- Business Quant data shows CAPR's Other Operating Expenses at -$81143.0 in Q1 2026, -$6846.0 in Q3 2025, and -$150673.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Capricor Therapeutics | 545.09 Mn | 545.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -81,143.00 |
| Sep 30, 2025 | -6,846.00 |
| Mar 31, 2025 | -150,673.00 |
| Sep 30, 2024 | -1.14 Mn |
| Dec 31, 2023 | -653.00 |
| Sep 30, 2023 | -5,388.00 |
| Mar 31, 2023 | -38,481.00 |
| Dec 31, 2022 | -34,266.00 |
| Jun 30, 2022 | -34,912.00 |
| Dec 31, 2021 | -28,955.00 |
| Jun 30, 2021 | -2,725.00 |
| Mar 31, 2021 | -3,678.00 |
| Mar 31, 2020 | -44,844.00 |
| Jun 30, 2019 | -2,720.00 |